RxDoctor Payments Data

Sarah Sunshine, MD

Ophthalmology · Chicago, ILNPI 1275978223

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $53,245 of the $55,755 with a category attached, or 95.5%. 7 manufacturers reported payments, led by Kamada Ltd. at 41.6% of the total. Reporting peaked in 2024 at $31,752 and has fallen 69.6% since, to $9,664 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,755in general payments, 2019–2025

Across 34 payments — averaging $1639.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kamada Ltd.$23K
  • GSK$18K
  • AstraZeneca$9K
  • Astrazeneca UK Limited$3K
  • Sanofi$2K
  • Alcon$192
  • plus $28 from 1 others
$608,697in research payments, 2019–2025

Across 2 payments — averaging $304,348 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$609K

What the payments were for

  • Consulting fees$53,24595%
  • Travel & lodging$1,1622%
  • Food & beverage$1,2792%
  • Education$690%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Kamada Ltd.1$23,200
GSK14$18,183
AstraZeneca9$9,137
Astrazeneca UK Limited4$3,083
Sanofi1$1,932
Alcon4$192
Novartis1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,755 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$57,435
Medicare patients
175
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$28,791
Loteprednol Etabonate18$4,378
Travoprost12$2,883
Prednisolone Acetate30$2,612
MoxifloxacinMoxifloxacin Hcl38$782
ErythromycinErythromycin Base41$607

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →